A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
BUSINESS
JCR Hits 1st Milestone in Alexion Collab for Neurodegenerative Disease
JCR Pharmaceuticals said on March 19 that it has met the first research milestone under its collaboration with Alexion, the rare disease arm of AstraZeneca, targeting neurodegenerative diseases. As per the terms of the deal, which aims to carve out…
To read the full story
Related Article
- JCR, Alexion Tie Up to Develop Oligonucleotide Therapeutics
December 21, 2023
- JCR, Alexion Pair Up for Neurodegenerative Disease
March 31, 2023
BUSINESS
- Japan Ethical Drug Sales Jump 9.7% in September: Crecon
November 11, 2025
- Kaken’s KP-001 Hits Goal in PIII Vascular Malformation Trial
November 11, 2025
- MSD Japan Chief Voices Regret over Delay in Routine HPV Shots for Males
November 10, 2025
- J&J Files Oral Psoriasis Drug Icotrokinra in Japan
November 10, 2025
- Keytruda Still Dominates Japan Drug Market in October: Encise
November 10, 2025
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…